Home › Myelodysplastic Syndromes › Maryland
Myelodysplastic Syndromes clinical trials in Maryland
23 studies for Myelodysplastic Syndromes are looking for participants at sites in Maryland.
Cities in Maryland
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Oct 2, 2026 · NCT06303193Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06577441Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06904066Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
1 Day – 99 Years · All sexes · Updated Oct 2, 2026 · NCT07683104Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 4 to 75 · All sexes · Updated Oct 1, 2026 · NCT03173937CHIP/CCUS Natural History Protocol
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT04102423MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 4 to 80 · All sexes · Updated Sep 22, 2026 · NCT01174108Natural History Study of GATA2 Deficiency and Related Disorders
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 22, 2026 · NCT01905826Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Maryland Oncology Hematolofy, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- The Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT04419649Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 23, 2026 · NCT05588154Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Day – 120 Years · All sexes · Updated Jul 23, 2026 · NCT05350748A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 10, 2026 · NCT05027945Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
1 Month – 120 Years · All sexes · Updated Jul 6, 2026 · NCT07019155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingEarly phase 1
Ages 18 to 100 · All sexes · Updated Mar 27, 2026 · NCT07071155A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 23, 2025 · NCT04245397SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- and 1 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.